Anatomy & Neurobiology - Center for Microelectrode Technology

Publications (2006)

1. Adderall® produces increased striatal dopamine release and a prolonged time course compared to amphetamine isomers. Joyce BM, Glaser P, and Gerhardt G. Psychopharmacology Oct 10, 2006; [Epub ahead of print]
2. Second-by-second measurement of acetylcholine release in prefrontal cortex. Bruno JP, Gash C, Martin B, Zmarowski A, Pomerleau F, Burmeister J, Huettl P and Gerhardt GA. Eur J Neurosci. 24(10):2749-57, 2006.
3. Assessing nigrostriatal dysfunctions by pharmacological MRI in parkinsonian rhesus macaques. Zhang Z, Andersen AH, Ai Y, Loveland A, Hardy PA, Gerhardt GA and Gash DM. Neuroimage 33(2):636-43, 2006.
4. Reduced Plasma Membrane Surface Expression of GLAST Mediates Decreased Glutamate Regulation in the Aged Striatum. Nickell JR, Salvatore MF, Pomerleau F, Apparsundaram S and Gerhardt GA. Neurobiology of Aging (in press) [Epub ahead of print] Sep 5 2006.
5. Point source concentration of GDNF may explain failure of Phase II clinical trial. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, Gerhardt GA and Gash DM. Exp Neurol 202(2):497-505, 2006.
6. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Slevin JT, Gash DM, Smith CD, Gerhardt GA, Kryscio R, Chebrolu H, Walton A, Wagner R, and Young AB. Neurosurg Focus 20(5):E1, 2006.
7. Reply: GDNF poses troubling questions for doctors, drug maker. Slevin JT, Gerhardt GA, Smith CD, Gash DM, and Young AB. Ann Neurol. 59(6):989-990, 2006.
8. MRI Volumetric and intensity analysis of the cerebellum in Parkinson’s disease patients infused with glial-derived neurotrophic factor (GDNF). Chebrolu H, Slevin JT, Gash DM, Gerhardt GA, Young BA and Smith CD. Exp Neurol 198(2):450-6, 2006.
9. Microelectrode array studies of basal and potassium-evoked release of L-glutamate in the anesthetized rat brain. Day BK, Pomerleau F, Burmeister J, Huettl PF, and Gerhardt GA. J Neurochem Mar;96(6):1626-35, 2006.
10. GDNF in treatment of Parkinson's disease: response to editorial. Penn R, Dalvi A, Slevin J, Young B, Gash D, Gerhardt GA, Hutchinson M. The Lancet Neurology, 5(3): 202-203, 2006.
11. Towards a neuroscience of attention-deficit/hyperactivity disorder: Fractionating the phenotype. Castellanos FX, Glaser PEA and Gerhardt GA. J Neurosci Methods. Feb 15;151(1):1-4, 2006.
12. Does dopamine neurotransmission occur in the cerebellar vermis? Cerebellar neurotransmission in attention-deficit/hyperactivity disorder. Glaser PEA, Surgener SP, Grondin R, Gash CR, Palmer M, Castellanos FX and Gerhardt GA. 2006 J Neurosci Methods Feb 15;151(1):62-67, 2006.
13. Monoamine metabolism and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice. Fernandez E, Koek W, Ran Q, Gerhardt GA, France CP and Strong R. Alcohol Clin Exp Res 30(10):1650-8, 2006.